Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

doi:10.3748/wjg.v21.i23.7281

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9632)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

560

WORD

230

HTML

3998

Figures (1-2)

326

Tables (1-3)

285

Sum=5399

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1491

Download

2742

Sum=4233

Jun 21, 2015 (publication date) through Apr 13, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Jun 21, 2015; 21(23): 7281-7288
Published online Jun 21, 2015. doi: 10.3748/wjg.v21.i23.7281

Table 2 Overall response rate of the intention-to-treat population

	n (%)¹
CR (best overall response)	10 (5.1)
PR	87 (44.2)
SD	55 (27.9)
CB (CR + PR + SD)	152 (77.1)
PD	13 (6.6)
No tumor assessment	32 (16.2)

¹Values reported as number of patients and, in parentheses, percentage on total number of patients. CB: Clinical benefit; CR: Complete response; ITT: Intention-to-treat; PD: Progressive disease; PR: Partial response; SD: Stable disease.

Citation: Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288
URL: https://www.wjgnet.com/1007-9327/full/v21/i23/7281.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i23.7281